Protexeon Limited
London, GB· latest recorded location
Protexeon Limited is named on 4 US grants and 5 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 4
- Published applications
- 5
- Inventors
- 2
- Granted in 2026 so far
- 0
- Most recent grant
- 15 Dec 2009
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 2 | 0 |
| 2009 | 1 | 1 |
By publication year.
Technology areas
Share of 9 documents
Recent patents
- Analgesic agent for newborn or fetal subjects15 Dec 2009US 7,632,872 B2
- Use of xenon for the control of neurological deficits associated with cardiopulmonary bypass28 Oct 2008US 7,442,383 B2
- Use of xenon with hypothermia for treating neonatal asphyxia24 Jun 2008US 7,390,508 B2
- NMDA antagonist comprising xenon25 Nov 2003US 6,653,354 B2
- Use of xenon as neuroprotectant in a neonatal subject17 Dec 2009US 2009/0311340 A1
- Use of xenon with hypothermia for treating neonatal asphyxia10 May 2007US 2007/0104796 A1
- Analgesic agent for newborn or fetal subjects19 Oct 2006US 2006/0233885 A1
- Use of xenon for the control of neurological deficits associated with cardiopulmonary bypass27 Oct 2005US 2005/0238726 A1
- NMDA antagonist6 Jun 2002US 2002/0068764 A1
Most cited
By later US patents
- NMDA antagonist comprising xenon20US 6,653,354 B22003
- Use of xenon with hypothermia for treating neonatal asphyxia6US 7,390,508 B22008
- Analgesic agent for newborn or fetal subjects5US 7,632,872 B22009
- Use of xenon for the control of neurological deficits associated with cardiopulmonary bypass4US 7,442,383 B22008